Scenario drafting for early technology assessment of next generation sequencing in clinical oncology

por Joosten, S.E.P., Retèl, V.P., Coupé, V.M.H., van den Heuvel, M.M., van Harten, W.H.
Publicado 2016

Soluble epidermal growth factor receptor (sEGFR) and carcinoembryonic antigen (CEA) concentration in patients with non-small cell lung cancer: correlation with survival after erlot...

por Kappers, I, Vollebergh, M A, van Tinteren, H, Korse, C M, Nieuwenhuis, L L, Bonfrer, J M G, Klomp, H M, van Zandwijk, N, van den Heuvel, M M
Publicado 2010

Presence of a 34-gene signature is a favorable prognostic marker in squamous non-small cell lung carcinoma

por Theelen, W. S. M. E., Krijgsman, O., Monkhorst, K., Kuilman, T., Peters, D. D. G. C., Cornelissen, S., Ligtenberg, M. A., Willems, S. M., Blaauwgeers, J. L. G., van Noesel, C. J. M., Peeper, D. S., van den Heuvel, M. M., Schulze, K.
Publicado 2020

Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib

por de Haan, R., van Werkhoven, E., van den Heuvel, M.M., Peulen, H. M. U., Sonke, G. S., Elkhuizen, P., van den Brekel, M. W. M., Tesselaar, M. E. T., Vens, C., Schellens, J. H. M., van Triest, B., Verheij, M.
Publicado 2019